Effectively treating Alzheimer’s disease has been one of the most significant failures of the pharmacological industry. Yet Alzheimer’s can be viewed as a metabolic disorder driven by increasing insulin resistance (1). Thus, it seems intuitive that reducing insulin resistance should be the primary tool to both prevent and treat the symptoms of Alzheimer’s. So, where to start? The most likely candidate is increasing AMPK activity (2). As to why it works is a little more complicated.
It starts with the approval in 2002 for using lithium salts to treat bipolar depression and especially manic episodes of bipolar depression (3). As to why it worked, no one seemed to know at the time. Now it appears that lithium activates AMPK. In particular, lithium inhibits the key enzyme (GSK3β) that inhibits AMPK activity (4). It makes more sense to me to activate AMPK directly and bypass using the lithium.
A recent article from Harvard Medical School confirms the potential benefits of lithium for treating Alzheimer’s (5). This new publication indicates that the earliest changes in patients with mild cognitive impairment, the precursor condition to Alzheimer’s, are related to low levels of lithium in the brain. In animal models prone to developing Alzheimer’s, adding lithium to their drinking water dramatically reduced the development of amyloid plaques in their brains. Of course, these benefits were strongly influenced by the type of lithium salt given to the animals, meaning there is a lot of work to do before such a drug will ever get clinical approval.
So why not start activating AMPK and not have to wait for some drug approval far in the future? You can start by using Metabolic Engineering® to begin activating AMPK with your next meal.
The foundation of Metabolic Engineering® is the calorie-restricted Zone diet, which continually activates AMPK and keeps it in a therapeutic zone. Adding high-dose omega-3 fatty acids to the Zone diet will further reduce neuroinflammation, another key component in the development of Alzheimer’s disease. Not surprisingly, it was found in 1999 that taking 9.6 grams of EPA and DHA daily had significant benefits in treating bipolar depression (6).
In my book, The OmegaRx Zone, I reported some of my early experiences using even higher doses with Alzheimer’s patients (7). Finally, add some polyphenols that indirectly activate AMPK, and you have the appropriate dietary system that reduces the likelihood of developing any chronic disease associated with insulin resistance. What are some of those chronic conditions? They include obesity, type 2 diabetes, cardiovascular disease, polycystic ovary syndrome (the primary cause of infertility), and neurological conditions such as Alzheimer’s, Parkinson’s, and depression.
How do you know if Metabolic Engineering® is working? The blood markers of Zone will tell you within a short period of time (one to three months). Your goal is to get to Zone and stay there for the rest of your life. The appropriate time to treat these chronic conditions associated with insulin resistance is years before they develop their clinical symptoms. Metabolic Engineering® provides the dietary pathway to change your future starting today.
References:
1. Yoon JH, Hwang J, Son SU, Choi J, You SW, Park H, Cha SY, Maeng S. How Can Insulin Resistance Cause Alzheimer’s Disease? Int J Mol Sci. 2023; 24:3506. doi: 10.3390/ijms24043506.
2. Chen M, Huang M, Liu J, Huang J, Shi J, Jin F AMPK: A Bridge Between Diabetes Mellitus and Alzheimer’s Disease. Behavioral Brain Research. 2021; 400:113043. doi.org/10.1016/j.bbr.2020.113043.
3. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry. 2002; 63 Suppl 10:5-12. PMID: 12392347.
4. Gherardelli C, Cisternas P, Inestrosa NC. Lithium Enhances Hippocampal Glucose Metabolism in an In Vitro Mice Model of Alzheimer’s Disease. Int J Mol Sci. 2022; 23:8733. doi: 10.3390/ijms23158733.
5. Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, Hamplova SE, Lacey EK, Roche P, Yuan M, Hazaveh SS, Lee EA, Bennett DA, Yankner BA. Lithium Deficiency and the Onset of Alzheimer’s Disease. Nature. 2025; 645:712-721. doi: 10.1038/s41586-025-09335-x.
6. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega-3 Fatty Acids in Bipolar Disorder: A Preliminary Double-Blind, Placebo-Controlled Trial. Arch Gen Psychiatry. 1999; 56:407-12. doi: 10.1001/archpsyc.56.5.407.
7. Sears B. The OmegaRx Zone. Regan Books. New York, NY (2001)
